European Journal of Clinical Pharmacology

, Volume 42, Issue 2, pp 159–161

0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream

  • H. C. Korting
  • D. Vieluf
  • M. Kerscher
Originals

DOI: 10.1007/BF00278477

Cite this article as:
Korting, H.C., Vieluf, D. & Kerscher, M. Eur J Clin Pharmacol (1992) 42: 159. doi:10.1007/BF00278477

Summary

The atrophogenic potential of medium-potent topical glucocorticoids is still controversial. In a double-blind controlled trial 24 healthy volunteers either applied 0.25% prednicarbate cream or the corresponding vehicle to one and 0.1% betamethasone-17-valerate cream or 0.05% clobetasol-17-propionate cream to the other forearm twice daily. Skin thickness was regularly assessed during the six week period of application and for further three weeks thereafter, using both the B- and A-mode of a 20 MHz ultrasound scanner.

Both betamethasone-17-valerate and clobetasol-17-propionate cream significantly reduced skin thickness as compared to cream base while prednicarbate cream did not.

Given that 0.1% betamethasone-17-valerate- and 0.25% prednicarbate cream are reported to be about equipotent in the treatment of atopic eczema the latter preparation shows an increased ratio between its desired anti-inflammatory and its unwanted atrophogenic effect.

Key words

Skin atrophy Prednicarbate cream ultrasound betamethasone-17-valerate-cream clobetasol-17-propionate cream adverse effects skin atrophy 

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • H. C. Korting
    • 1
  • D. Vieluf
    • 1
  • M. Kerscher
    • 1
  1. 1.Department of DermatologyLudwig-Maximilians-UniversitätMunichFRG

Personalised recommendations